Predicta develops a blood-based oncology platform that utilizes multi-omics and liquid biopsy technologies to provide non-invasive diagnostics, replacing the need for bone marrow biopsies. This approach enables early disease detection and personalized treatment guidance, improving patient outcomes through actionable insights derived from comprehensive patient data analysis.
Funding
$5.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for diagnosing and monitoring blood cancers often rely on invasive bone marrow biopsies, which are painful, carry risks, and provide a limited snapshot of the disease. These biopsies may also delay diagnosis and treatment decisions, hindering optimal patient outcomes.
Solution
Predicta offers a blood-based oncology platform that utilizes multi-omics and liquid biopsy technologies to provide non-invasive diagnostics for blood cancers. The platform analyzes genomic and transcriptomic data from routine blood draws, eliminating the need for invasive bone marrow biopsies. By applying AI and machine learning to a growing database of patient data, Predicta's platform enables early disease detection, accurate diagnosis, and personalized treatment guidance. The platform delivers actionable insights to physicians, helping them identify the most effective therapies and improve patient outcomes.
Target Audience
The primary target audience includes oncologists, hematologists, and other healthcare professionals involved in the diagnosis and treatment of blood cancers, as well as pharmaceutical companies seeking to develop novel therapies.
Features
- Non-invasive blood draw replaces the need for bone marrow biopsies.
- Multiomic analysis, including genomics and transcriptomics, provides a detailed understanding of the disease.
- AI/ML algorithms analyze patient data to identify therapeutic approaches.
- Growing patient database enhances diagnostic and therapeutic discovery tools.
- Concise reports deliver actionable insights for personalized treatment guidance.
- Platform enables early detection, accurate diagnosis, and improved monitoring of blood cancers.